Do you have a child or teen suffering from migraine?
Pediatric Migraine Clinical Trial
Biohaven Pharmaceuticals is studying an investigational drug, called rimegepant, for the acute treatment of migraines in the pediatric population. If your child is between 12 and 17 years of age and has at least a 6-month history of migraine, they may qualify. The investigational drug, plus all study-related assessments, will be provided at no cost to you.
Health insurance is not required to take part in this study and compensation for participation may also be provided.
Who is this study for?
Teens may qualify for this study if they meet the following criteria:
Between the ages of 12 and 17
Have at least 1 migraine per month
Have at least a 6-month history of migraine
The migraine study clinicians will further assess medical and migraine history to determine eligibility.
Participants may receive:
Study-related evaluations and care, including the investigational study drug.*
Compensation for participation may be provided.
*Insurance not needed to participate.